Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Almut Scherer

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Arthritis Research & Therapy|July 21, 2017
Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritisRaphael Micheroli, Monika Hebeisen, Lukas M Wildi, et al.
British Journal of Haematology|April 4, 2019
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritisGodehard A Scholz, Alexander B Leichtle, Almut Scherer, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2004
Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDSAlmut Scherer, John Frater, Annette Oxenius, et al.
Rheumatology (Oxford, England)|May 17, 2022
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapyAndrea Amstad, Eleftherios Papagiannoulis, Almut Scherer, et al.
The Journal of Rheumatology|November 3, 2014
Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohortAdrian Ciurea, Ulrich Weber, Daniel Stekhoven, et al.
Annals of the Rheumatic Diseases|February 11, 2015
Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritisAdrian Ciurea, Almut Scherer, Ulrich Weber, et al.
RMD Open|December 6, 2023
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registryAdrian Ciurea, Andrea Götschi, René Bräm, et al.
Arthritis Research & Therapy|March 14, 2023
Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management RegistryVjara Popova, Seraphina Kissling, Raphael Micheroli, et al.
Plos One|March 21, 2020
Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohortMonika Hebeisen, Raphael Micheroli, Almut Scherer, et al.
Clinical Rheumatology|December 27, 2022
HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management RegistryFabienne Fröhlich, Raphael Micheroli, Monika Hebeisen, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Arthritis Research & Therapy|July 21, 2017
Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritisRaphael Micheroli, Monika Hebeisen, Lukas M Wildi, et al.
British Journal of Haematology|April 4, 2019
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritisGodehard A Scholz, Alexander B Leichtle, Almut Scherer, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2004
Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDSAlmut Scherer, John Frater, Annette Oxenius, et al.
Rheumatology (Oxford, England)|May 17, 2022
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapyAndrea Amstad, Eleftherios Papagiannoulis, Almut Scherer, et al.
The Journal of Rheumatology|November 3, 2014
Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohortAdrian Ciurea, Ulrich Weber, Daniel Stekhoven, et al.
Annals of the Rheumatic Diseases|February 11, 2015
Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritisAdrian Ciurea, Almut Scherer, Ulrich Weber, et al.
RMD Open|December 6, 2023
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registryAdrian Ciurea, Andrea Götschi, René Bräm, et al.
Arthritis Research & Therapy|March 14, 2023
Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management RegistryVjara Popova, Seraphina Kissling, Raphael Micheroli, et al.
Plos One|March 21, 2020
Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohortMonika Hebeisen, Raphael Micheroli, Almut Scherer, et al.
Clinical Rheumatology|December 27, 2022
HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management RegistryFabienne Fröhlich, Raphael Micheroli, Monika Hebeisen, et al.
Pageof 6